Vengefulness

Rak S. Lowhagen O, Venge P The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Chn Immunol 1988 82 470-480. 

Amin K, Janson C, Harvima I, Venge P, Nilsson G. CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma. J Allergy Clin Immunol 2005 116(6) 1383—1386. 

Inside This Astounding Collection You Will Discover Wondrous Storytellers, Vengeful Deities, Demons, Alchemists. .. 

P Veng-Pedersen. Linear and nonlinear systems approach in pharmacokinetics How much do they have to offer I. General considerations. J Pharmacokin Biopharm 16 413-472, 1988. 

Nimodipine is a racemic mixture (i.e., it is a compound in two mirror image forms, one of which is more active than the other). Veng et al. (2003) reported the reversal of... 

Veng LM, Mesches MH and Browning MD (2003). Age-related working memory impairment is correlated with increases in the L-type calcium channel protein alD (Cavl.3) in area CA1 of the hippocampus and both are ameliorated by chronic nimodipine treatment. Molecular Brain Research, 110, 193-202. 

P. Veng-Pedersen, N. B. Modi. Optimal extravascular dosing intervals. /. Pharmacokin. Biopharm. 1991, 19, 405-412. 

May it please the Tribunal, the indictment accuses these men of major responsibility for visiting upon mankind the most searing and catastrophic war in modem history. It accuses them of wholesale enslavement, plunder and murder. These are terrible charges no man should underwrite them frivolously or vengefully. There is no laughter in this case, neither is there any hate. 

Veng-Pedersen P, Gillespie W. The mean residence time of drugs in the systemic circulation. J Pharm Sci 1985 74 791-792. 

Gillespie, W.R. and Veng-Pedersen, P., A polyexponential deconvolution method evaluation of the gastrointestinal bioavailability and mean in vivo dissolution time of some ibuprofen dosage forms, /. Pharmacokinet. Biopharm., 13, 289-307, 1985. 

To be spiteful is to be vengeful or vindictive. The keys here are the word malice and the phrase almost ruined the referee s career. 

Veng-Pedersen P, Paustenback DJ, Carlson GP, et al. 1987. A linear systems approach to analyzing the pharmacokinetics of carbon tetrachloride in the rat following repeated exposures of 8 and 11.5 h/day. Arch Toxicol 60 355- 364. 

P. Veng-Pedersen, Novel deconvolution method for linear pharmacokinetic systems with polyexponential impulse response, J. Pharm. Sci.,... 

P. Veng-Pedersen, An algorithm and computer program for deconvolution in linear pharmacokinetics. J. Phar. Biopharm, 8 (1980) 463-481. 

Trulson A, Bystrom J, Engstrom A, Larsson R, Venge P. 2007. The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy. 37 208-218. 

Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, Trulson A. 1999. Eosinophil cationic protein (ECP) Molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 29 1172-1186. 

Young J, Peterson C, Venge P, Cohn Z. 1986. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 321 613-616. 

Herman, R. A. and P. Veng-Pedersen. 1994. Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not con ned to a congeneric sefi harm. Sci83 423-428. 

W. R. Gillespie and P. Veng-Pedersen. The determination of mean residence time using statistical moments It is correct. J. Pharm. Biopharm. 13 549-554, 1985. 

P. Veng-Pedersen. Noncompartmentally based pharmacokinetic modeling. Adv. Drug Deliv. Rev. 48 265-300, 2001. 

In this quiet moment, Padorin felt the urge to draw away, but Dusha gripped his forearm and pulled him back within earshot of her furious whisper. You only need break the heart of one, Victor Ilyich, she blazed like a vengeful archangel, and I swear I will kill you ... 

Veng-Pedersen, P. and Modi, N., Optimal extravascular dosing intervals, Journal of Pharmacokinetics and Biopharmaceutics, Vol. 19, No. 4, 1991, pp. 405-412. 

Venge P, Lagerquist B, Diderholm E, et al. on behalf of the FRISC II Study Group Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC n Substudy).Am J Cardiol 89 1035-1041, 2000. 

---